Andy/iStock via Getty Images Editas Medicine (NASDAQ:EDIT) plans to slash around 180 jobs, or approximately 65% of its ...

Editas plans to lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell ...

The gene-editing technique is effective for treating some illnesses but it's been too expensive to consider it for rare ...

The company had said in October said that it was looking to license out its ex vivo editor renizgamglogene autogedtemcel to ...

Emma Reeve, the chair of Editas’ board, is also resigning, to be replaced by Jessica Hopfield, Ph.D., the company explained ...

Barclays analyst Gena Wang maintained a Hold rating on Editas Medicine (EDIT – Research Report) today and set a price target of $3.00. The ...

The latest group of winning technologies has a little something for everyone—from scientists at the lab bench to those in the ...

Editas Medicine said on Thursday it would cut around 180 jobs, representing 65% of its workforce, over the next six months as part of the company's transition towards becoming a developer of therapies ...

Doing CRISPR gene editing while fetuses are in the womb could make it easier to treat inherited conditions, especially those affecting tissues such as the heart or muscles. Kiran Musunuru at the ...

CRISPR Therapeutics stock has lost nearly half its value since peaking in March. The launch of the company's first drug, Casgevy, has been very slow. Aside from Casgevy, it has five clinical-stage ...

Perform CRISPR guide mapping and analysis that considers protospace self-editing and surrogate sensor sequences. Self-editing aware mapping takes a hamming-distance approach unbiased by expectations ...